Sökning: "Ulrika Simonsson"

Visar resultat 1 - 5 av 10 avhandlingar innehållade orden Ulrika Simonsson.

  1. 1. Pharmacometric tools to support translational drug development

    Författare :Rami Ayoun Alsoud; Ulrika S. H. Simonsson; Michael Lyons; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; drug development; pharmacometrics; pharmacokinetics; pharmacodynamics; non-linear mixed effect models; tuberculosis; dose selection; interspecies scaling; pediatric trials; Farmaceutisk vetenskap; Pharmaceutical Science;

    Sammanfattning : The use of model-informed drug development has been shown to save significant costs and improve decision making early in the drug development process. The work in this PhD thesis aimed to employ pharmacometric tools to support translational drug development from the preclinical to the late clinical stages. LÄS MER

  3. 2. Pharmacometric Models in Anesthesia and Analgesia

    Författare :Marcus Björnsson; Ulrika Simonsson; Mats Karlsson; Leonid Gibiansky; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; Anesthesia; Analgesia; Dropout; NONMEM; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Sammanfattning : Modeling is a valuable tool in drug development, to support decision making, improving study design, and aid in regulatory approval and labeling. This thesis describes the development of pharmacometric models for drugs used in anesthesia and analgesia. LÄS MER

  4. 3. Pharmacokinetics and Pharmacodynamics of Oxycodone and Morphine with Emphasis on Blood-Brain Barrier Transport

    Författare :Emma Boström; Margareta Hammarlund-Udenaes; Ulrika Simonsson; Danny D Shen; Uppsala universitet; []
    Nyckelord :Pharmacokinetics Pharmacotherapy; pharmacokinetics; pharamcodynamics; blood-brain barrier; oxycodone; microdialysis; NONMEM; brain distribution; transport; Farmakokinetik Farmakoterapi;

    Sammanfattning : The pharmacokinetics and pharmacodynamics of oxycodone and morphine was investigated and related to the transport across the blood-brain barrier (BBB) in rats. The influence of a P-glycoprotein (P-gp) inhibitor on the plasma pharmacokinetics and pharmacodynamics of oxycodone was evaluated. LÄS MER

  5. 4. Pharmacokinetic-Pharmacodynamic Evaluations and Experimental Design Recommendations for Preclinical Studies of Anti-tuberculosis Drugs

    Författare :Chunli Chen; Ulrika Simonsson; Mats Karlsson; Sebastian Wicha; Bernd Meibohm; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; tuberculosis; pharmacokinetics; pharmacodynamics; pharmacometrics; the Multistate Tuberculosis Pharmacometric model; the General Pharmacodynamic Interaction model; optimized design; rifampicin; isoniazid; ethambutol; pyrazinamide; Pharmaceutical Science; Farmaceutisk vetenskap;

    Sammanfattning : Tuberculosis is an ancient infectious disease and a leading cause of death globally. Preclinical research is important for defining drugs and regimens which should be carried forward to human studies. LÄS MER

  7. 5. Novel Pharmacometric Methods for Informed Tuberculosis Drug Development

    Författare :Oskar Clewe; Ulrika S.H. Simonsson; Mats O. Karlsson; Piet van der Graaf; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacokinetics; pharmacodynamics; PKPD; pharmacometric; nonlinear mixed-effects models; multistate tuberculosis pharmacometric model; general pharmacodynamic interaction model; general pulmonary distribution model; tuberculosis; rifampicin; isoniazid; ethambutol; Pharmaceutical Science; Farmaceutisk vetenskap;

    Sammanfattning : With approximately nine million new cases and the attributable cause of death of an estimated two millions people every year there is an urgent need for new and effective drugs and treatment regimens targeting tuberculosis. The tuberculosis drug development pathway is however not ideal, containing non-predictive model systems and unanswered questions that may increase the risk of failure during late-phase drug development. LÄS MER